NK-92

Global NK Cell Therapies 2022: Insights into 80+ Companies and 100+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, February 18, 2022

This report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in NK Cell therapy pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in NK Cell therapy pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence NK Cell therapy R&D.
  • The therapies under development are focused on novel approaches to treat/improve NK Cell therapy.
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of NK Cell therapy?

ImmunityBio Awarded Seminal Patent on Natural Killer Cells

Retrieved on: 
Tuesday, January 4, 2022

ImmunityBios NK-92 cells are specifically modified versions of the NK cells that are a core element of the human immune system.

Key Points: 
  • ImmunityBios NK-92 cells are specifically modified versions of the NK cells that are a core element of the human immune system.
  • First discovered in the blood of a non-Hodgkins lymphoma patient, these cells retain most of the activating receptors of NK cells but lack the major inhibitory receptors, giving them higher baseline cytotoxicity against tumor cells.
  • A growing body of research suggests that clinically meaningful responses to these antibody therapies is dependent upon the overall health of the patients own natural killer cells and whether the cells express the high-affinity variant of the CD16 receptors, which are found on the surface of natural killer cells.
  • The new patent adds another asset to ImmunityBios strong intellectual property portfolio, which includes more than 1,100 issued and pending patents worldwide across multiple categories including biologics, vaccine vectors, natural killer cells, and GMP devices.

GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021

Retrieved on: 
Wednesday, December 8, 2021

"B7-H3 is a checkpoint molecule under intense investigation as an immune therapy target for solid and hematologic tumors.

Key Points: 
  • "B7-H3 is a checkpoint molecule under intense investigation as an immune therapy target for solid and hematologic tumors.
  • Dr. Miller's lab previously showed that dual camelid nanobody tri-specific killer engager (TriKE) (GTB-5550) specifically bound B7-H3 on PC3/C4-2 prostate cancer (PCa) cells and activated peripheral blood (PB) NK cells.
  • We have since developed a dual camelid bispecific killer engager (BiKE) targeting B7-H3 and show that both GTB-5550, which harbors wild-type IL-15, and BiKE display broad activity against B7-H3-expressing tumors.
  • The data demonstrated that the novel dual camelid nanobody BiKE and GTB-5550 induce NK cell activation against a broad spectrum of tumors expressing B7-H3.

FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors

Retrieved on: 
Monday, May 17, 2021

Based on the novel techniques and cytokine expansion developed at ImmunityBio, a single apheresis will enable 10 to 20 doses of m-ceNK infusions of 0.5 billion NK cells per dose.

Key Points: 
  • Based on the novel techniques and cytokine expansion developed at ImmunityBio, a single apheresis will enable 10 to 20 doses of m-ceNK infusions of 0.5 billion NK cells per dose.
  • These autologous and allogeneic cryopreserved memory NK cells could synergize with our engineered off-the-shelf NK-92 cells, as well as with our IL-15 Anktiva superagonist, which stimulates both NK and T cells.
  • A 2 to 3 log-fold expansion of activated NK cells was achieved by the third week of the protocol.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings

Retrieved on: 
Monday, March 22, 2021

INKmune is a clinical stage proprietary tumor cell line which is administered intravenously and primes NK cells to kill otherwise resistant tumors.

Key Points: 
  • INKmune is a clinical stage proprietary tumor cell line which is administered intravenously and primes NK cells to kill otherwise resistant tumors.
  • INKmune-primed NK cells have been shown to kill a wide variety of solid and hematological cancer cells in preclinical studies.
  • INKmune-primed NK cells have a mRNA fingerprint which is fundamentally different to NK cells activated with IL-2 or IL-15.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies

Retrieved on: 
Friday, February 26, 2021

Artiva Biotherapeutics , Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a $120 million Series B financing.

Key Points: 
  • Artiva Biotherapeutics , Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a $120 million Series B financing.
  • Artiva plans to use the proceeds from the financing to advance its NK cell therapy development programs and expand ongoing research and development activities.
  • Artivas cell therapies are designed to leverage the innate anti-tumor biology and safety features of NK cells.
  • Artivas manufacturing platform supports large-scale production and cryopreservation of off-the-shelf allogeneic NK cell therapies, and proprietary CAR-NK and NK-specific gene-editing technologies to augment therapeutic activity.

Artiva Biotherapeutics Announces FDA Allowance of IND to Initiate Clinical Trials of AB-101 in Combination with Rituximab for the Treatment of Advanced B-cell Lymphomas

Retrieved on: 
Monday, December 7, 2020

AB-101 is a cryopreserved NK cell product candidate with high and consistent expression of tumor-engaging receptors including the high-affinity variant of CD16.

Key Points: 
  • AB-101 is a cryopreserved NK cell product candidate with high and consistent expression of tumor-engaging receptors including the high-affinity variant of CD16.
  • These NK cell attributes have demonstrated improved outcomes for cancer patients in both the transplant and therapeutic monoclonal antibody settings.
  • Allogeneic NK cells have been tested in clinical trials for more than a decade.
  • Artivas pipeline of universal and targeted NK cell therapies leverages the innate anti-tumor biology and safety features of NK cells.

Affimed Announces Dosing of First Patient in Phase 1 Clinical Trial of Cord Blood-derived Natural Killer Cells in Combination with the Innate Cell Engager AFM13

Retrieved on: 
Tuesday, October 6, 2020

This novel combination approach could lay the groundwork for future cellular therapy combinations with Affimed ICE constructs.

Key Points: 
  • This novel combination approach could lay the groundwork for future cellular therapy combinations with Affimed ICE constructs.
  • An NK cell armed with AFM13 is designed to direct NK cells to the tumor site in order to target cancer cells.
  • Although larger numbers of NK cells in patients is associated with better outcomes, the adoptive transfer of non-targeted NK cells has shown only limited clinical benefit.
  • In preclinical models, combining AFM13 with adoptive NK cell transfer has been shown to enhance the efficacy of NK cells.

NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit

Retrieved on: 
Monday, September 21, 2020

NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6, 2020 at 12:50 PM ET.

Key Points: 
  • NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6, 2020 at 12:50 PM ET.
  • NantKwest (NASDAQ: NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases.
  • NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies.
  • The activated NK cell platform is designed to destroy cancer and virally-infected cells.

Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH

Retrieved on: 
Thursday, September 10, 2020

Brink Biologics, Inc. (Brink), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwests proprietary off-the-shelf NK-92 natural killer cells in certain fields, announces the licensing of its next-generation natural killer-based bioanalytical testing solution to Fresenius Kabi SwissBioSim GmbH (Fresenius), a Switzerland-based global healthcare company focusing on autoimmune diseases and oncology.

Key Points: 
  • Brink Biologics, Inc. (Brink), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwests proprietary off-the-shelf NK-92 natural killer cells in certain fields, announces the licensing of its next-generation natural killer-based bioanalytical testing solution to Fresenius Kabi SwissBioSim GmbH (Fresenius), a Switzerland-based global healthcare company focusing on autoimmune diseases and oncology.
  • Brink Biologics offers a variety of GLP and research-grade NK-92 based cell lines as part of its Neukopanel portfolio of products for laboratory testing applications.
  • Fresenius has joined the growing list of leading biotechnology companies that are using Brinks NK-92 cell line for laboratory based bioanalytical testing.
  • NEUKOPANEL is a trademark of Brink Biologics, Inc. For additional information and licensing inquiries, please visit www.brinkbiologics.com .